Compare NUVL & MUSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NUVL | MUSA |
|---|---|---|
| Founded | 2017 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Retail-Auto Dealers and Gas Stations |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1B | 7.2B |
| IPO Year | 2021 | N/A |
| Metric | NUVL | MUSA |
|---|---|---|
| Price | $104.39 | $405.15 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 7 |
| Target Price | $134.29 | ★ $476.50 |
| AVG Volume (30 Days) | ★ 828.0K | 239.0K |
| Earning Date | 10-30-2025 | 02-04-2026 |
| Dividend Yield | N/A | ★ 0.62% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 23.64 |
| Revenue | N/A | ★ $17,008,099,999.00 |
| Revenue This Year | N/A | $11.09 |
| Revenue Next Year | N/A | $3.18 |
| P/E Ratio | ★ N/A | $17.19 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $55.54 | $345.23 |
| 52 Week High | $112.88 | $556.87 |
| Indicator | NUVL | MUSA |
|---|---|---|
| Relative Strength Index (RSI) | 51.87 | 65.02 |
| Support Level | $103.52 | $381.58 |
| Resistance Level | $107.99 | $402.33 |
| Average True Range (ATR) | 3.18 | 11.51 |
| MACD | -0.93 | 2.01 |
| Stochastic Oscillator | 10.43 | 81.72 |
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
Murphy USA operates more than 1,700 fueling stations and convenience stores primarily across the Midwest and Southeastern United States. The firm owns about 75% of its locations, with most stores situated in high-traffic areas near Walmart supercenters. Murphy's stores typically range from 1,400-2,800 square feet, with most of its in-store sales derived from tobacco and nicotine products. The company acquired about 150 QuickChek stores in 2021, boosting its presence in grocery and foodservice. Murphy generates about two thirds of its profit from fuel retailing, with the remaining third coming from in-store sales.